Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$72.57+3.08(+4.43%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

BMY · NYSE

Bristol-Myers Squibb Company

$62.01 -1.00 (-1.59%)

Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
Market cap
$127B
Employees
34,100
Headquarters
Princeton, NJ
Website
bms.com
CEO
Christopher S. Boerner
Listed
June 1, 1972
P/E
17.42
Dividend yield
4.12%

Company financials

Revenue
$48.5B
Gross profit
$33.3B
Operating income
$12.4B
EBITDA
$13.8B
Net income
$7.3B
EPS
$3.56
Total assets
$86.5B
Total debt
$44.5B
Gross margin
68.75%
Net margin
15.01%
Earnings yield
5.74%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

52.8356.9461.0465.1469.25
BMY 1D NYSE O61.46H63.59L61.04C63.00+1.88 (+3.08%)Vol15.17M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
BMY Stock news What's Going On with Bristol Myers Squibb Stock on Friday? Benzinga
BMY Stock news BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? Zacks Investment Research
BMY Stock news Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 Business Wire
BMY Press release Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions Business Wire
BMY Press release Tempus Expands Strategic Collaboration with Bristol Myers Squibb Business Wire
BMY Press release Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline Business Wire
BMY Stock news Bristol Myers, SystImmune drug cuts breast cancer progression risk in study Reuters
BMY Press release Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study Business Wire
BMY Stock news Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? The Motley Fool
BMY Stock news A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Value $56.81 vs Price $63.00 GuruFocus
BMY Stock news Bristol Myers Squibb vs. Pfizer: Consistency vs. The Motley Fool
BMY Stock news Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. The Motley Fool
BMY Stock news Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? The Motley Fool
BMY Stock news Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow 24/7 Wall Street
BMY Press release Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 Business Wire
BMY Stock news Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? The Motley Fool
BMY Stock news AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors? 24/7 Wall Street
BMY Stock news Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
BMY Stock news Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know 24/7 Wall Street
BMY Stock news Top Pharmaceutical Stocks To Watch Now – October 13th Defense World
See more
FAQ

Questions about Bristol-Myers Squibb Company

What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
What is BMY's market cap?
Bristol-Myers Squibb Company (BMY) is a listed stock with a live quote. The latest market cap on this page is $127B.
Where is Bristol-Myers Squibb Company headquartered?
Bristol-Myers Squibb Company is headquartered in Princeton, NJ.
How do I get BMY news from the API?
Call GET /v1/news?tickers=BMY. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does BMY news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BMY, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the BMY price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs